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CASE REPORTS
Splicing mutation in 
TAZ gene leading to 
exon skipping and Barth 
syndrome
Larysa Sivitskaya1, Nina Danilenko1, Iryna Motuk2, Nikolai Zhelev3,4 
1 Institute of Genetics and Cytology, National Academy of Sciences, Minsk, 
Belarus; 2 Medical Genetic Department of Regional Perinatal Center, Grodno, 
Belarus; 3 School of Medicine, University of Dundee, Scotland, UK; 4 Medical 
University Plovdiv, Bulgaria
Barth syndrome is a monogenic X-linked disorder characterized by cardiomyop-
athy, skeletal myopathy and neutropenia. It is caused by deficiency of cardiolipin 
and associated with mutations in the tafazzin gene (TAZ). A 3 years old boy with 
dilated cardiomyopathy, neutropenia and growth retardation was investigated. 
Genetic screening found a new variant in the junction of intron 2 and exon 3 of the 
TAZ gene - c.239-1_239delinsTT. Functional analysis of the variant revealed the 
aberrant splicing of exon 3 leading to its complete excision from mature mRNA 
and frameshift at the beginning of tafazzin. Variant c.239-1_239delinsTT can be 
classified as pathogenic based on splicing alteration and typical clinical phenotype 
observed in TAZ mutation carriers.
Key words: Barth syndrome, TAZ, aberrant splicing, dilated cardiomyopathy, ex-
on skipping
Introduction
Barth syndrome (BTHS) was originally described in 1983 as an 
X-linked syndrome of dilated cardiomyopathy, skeletal myopathy and neu-
tropenia causing death in male infancy or early childhood 1. This syndrome 
is associated with mutations in the tafazzin (TAZ) gene at Xq28 that lead to 
cardiolipin deficiency and abnormal mitochondria 2,3. Tafazzin participates 
in the synthesis of mature cardiolipin (CL) – the necessary component of 
the mitochondrial membrane, critical for high-energy demand tissues  4. 
Lowered tafazzin activity destroys the formation of OXPHOS supercom-
plexes, mainly in the myocardium tissue and to the cardio-specific loss of 
the SDH, all these defects lead to the cardiomyopathy 5. 
Several phenotypes have been associated with BTHS: dilated cardio-
myopathy (most common), left ventricular noncompaction, endocardial 
fibroelastosis, hypertrophic cardiomyopathy. All these types are associated 
with the lack or massive suppression of CL synthesis and, as a result, with 
mitochondrial dysfunction 6.
Neutropenia, another main sign of BTHS, is typically observed in 
~  70% of patients and can be chronic or cyclic and doesn’t depend on 
patient’s age 7,8. It can be more (< 500 cells/mcl) or less (1,000-1,500 cells/
mcl) severe; as a result various infections have been reported: recurrent 
mouth ulcers (4 and more episodes per year), pneumonia, blood infections 
and others 8. 
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Muscle weakness – the third sign of the syndrome, is 
predominantly proximal and non-progressive during child-
hood. Most boys have more or less delayed gross motor 
milestones, then in adolescence they are able to walk but 
often find it hard to kick the ball or to run; up to 18 they 
usually reach normal height and body mass index 4,9.
We present a clinical report of dilated cardiomyopathy 
(DCM), neutropenia and skeletal myopathy associated with 
a TAZ splice site mutation in a 3 years old male patient. 
Case presentation 
The male patient was born with a weight of 2800 g 
and a body length of 50 cm. He is the second child in 
young unrelated parents. Since birth growth retardation 
(Tab.  I) and the motor delay were observed. The boy 
suffered from increased fatigue, physical intolerance. 
He showed mild microcytic, hypochromic anemia, cy-
clic neutropenia with neutrophil 6-18%. There was also 
a history of infectious illnesses. In the first year of his 
life, he was treated from acute bronchitis, pneumonia, 
obstructive bronchitis; in the second year – acute bron-
chitis, carbuncle of the upper lip. At the age of 3 years 
6 months, the boy was admitted to the intensive care unit 
with lethargy, pallor, puffy face, groaning breathing. 
Transthoracic echocardiography showed left ventricular 
dilatation: left ventricle (LV) diameters in end-diastole 
38  mm (LVEDD indexed to BSA –  69,1  mm/m2), LV 
end-diastolic volume index 126ml/m2, LV ejection frac-
tion 39%. Moderate hypertrophy of the LV myocardi-
um, predominantly of the posterior wall was observed. 
Moderate dilatation of the left atrium (LA) and right 
atrium (RA) was revealed (LA anterior-posterior and 
lateral-lateral diameters in the four-chamber 25*28 mm, 
RA anterior-posterior and lateral-lateral diameters right 
atrium 22*27  mm), right ventricle (RV) dimension in 
the four-chamber view was 20*36 mm. Right ventricu-
lar function wasn’t impaired (Tricuspid Annular Plane 
Systolic Excursion (TAPSE) – 12 mm). Mitral and tri-
cuspid regurgitation corresponded with II and I degrees. 
The aortic valve is tricuspid, a function is not impaired. 
The pulmonary artery pressure is not increased. A small 
amount of pericardial effusion was detected with sep-
aration of pericardial sheets along the anterior wall of 
the RA up to 3 mm. Acute myocarditis of unspecified 
aetiology was diagnosed. 
At the age of 4 years, the proband had hypostatura, 
blonde hair, rounded face, high, wide forehead, deep-set 
eyes, full cheeks, pointed chin, dimple under the lower 
lip, slightly protruding large ears. Speech development 
appropriated for his age. Parents noted the child prefer 
salty food with spices. 
Cytogenetic study of his peripheral lymphocytes 
showed normal karyotype 46, XY. Tandem mass spec-
trometry of dry blood spot didn’t reveal any significant 
disturbances.
Clinical examination of family members showed 
that proband’s parents and sister didn’t have any cardiac 
symptoms or abnormal cardiac studies.
Genetics study
Genomic DNA was obtained from buccal epitheli-
um by phenol/chloroform extraction. We performed the 
targeted next-generation sequencing (NGS) using the 
TruSight Cardiomyopathy sequencing kit on the MiSeq 
System (Illumina Inc., USA). List of 174 genes included 
in the NGS panel is presented in Table II.
The quality of raw NGS data was estimated with 
FastQC. The alignment was carried out with BWA against 
the reference genome NCBIbuild37 (UCSC hg19), the 
VCF files were generated with a GATK4 HaplotypeCall-
er. Variants were annotated by ANNOVAR using dbSNP 
IDs, NHLBI Exome Sequencing Project, The 1000 Ge-
nomes Project, the Genome Aggregation Database, Clin-
Var (2020), InterVar and REVEL. All the variations were 
classified according to the recommended method of the 
American College of Medical Genetics and Genomics. 
A variant c.239-1_239delinsTT was detected in junc-
tion of intron 2 and exon 3 of the TAZ gene (NM_000116). 
It is located in the canonical splice site and predicted to 
alter splicing according to the Human Splicing Finder. 
Sanger sequencing confirmed this variant. Segregation 
analysis revealed that the mutation appeared de novo. The 
patient’s mother and sister showed a normal sequence of 
the TAZ gene (Fig. 1). 
To confirm the alternative splicing of exon 3, total 
RNA of the patient and his mother were purified from 
Table I. Patient’s physical development data.
Age Weight (g) Percentiles Body length (sm) Percentiles
infant 2800 3-10 50 10-50
1 year 7100 < 3 70 < 3
2 years 2 months 9400 < 3 80 < 3
3 years 2 months 10.400 < 3 86 < 3
4 years 4 months 11.900 < 3 92 < 3
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whole blood using TRI reagent (Sigma-Aldrich, USA) 
according to the manufacturer’s instructions. Reverse 
transcription of the total RNA was performed with oli-
go-dT primers. RT-PCR was carried out with primers 
specific to exon-exon boundaries in the mature mRNA 
(transcript variant NM_000116; primer sequences avail-
able upon request). The expected size of the amplicons 
was 249 bp including the exons 1-4. The PCR-fragments 
were analyzed by electrophoresis in 2% agarose gel, ex-
tracted from gel and directly sequenced. 
Results and discussion
We identified new splice variant c.239-1_239delin-
sTT in TAZ gene of the boy with dilated growth retarda-
tion. He suffered from cardiomyopathy, cyclic neutrope-
nia and various infections, both local and systemic. We 
confirmed the alternative splicing of exon 3 due to this 
variant. RT-PCR analysis showed two different amplicons: 
249 bp in healthy mother (corresponds to the wild type) 
and 204 bp in patient (corresponds to the PCR-product 
without exon 3). Sequence analysis confirmed the variant 
c.239-1_239delinsTT led to the skipping of the exon 3 in 
the mature mRNA (Fig. 2). Thus the genetic reason for 
DCM in our patient was the complete excision of exon 3 
causing a frameshift at the beginning of tafazzin.
To date, 12 splicing mutations in the TAZ gene have 
been reported in ClinVar as pathogenic or likely patho-
genic. Several of them were found in the junction of in-
tron 2 and exon 3 of the TAZ gene. Probably all of them 
result in the aberrant splicing of exon 3, but the functional 
analysis has been conducted for few. Interestingly, other 
Table II. List of 174 genes included in the TruSight Cardiomyopathy sequencing kit (from Illumina Inc. USA, mod.).
ABCC9, ABCG5, ABCG8, ACTA1, ACTA2, ACTC1, ACTN2, AKAP9, ALMS1, ANK2, ANKRD1, APOA4, APOA5, APOB, 
APOC2, APOE, BAG3, BRAF, CACNA1C, CACNA2D1, CACNB2, CALM1, CALR3, CASQ2, CAV3, CBL, CBS, CETP, 
COL3A1, COL5A1, COL5A2, COX15, CREB3L3, CRELD1, CRYAB, CSRP3, CTF1, DES, DMD, DNAJC19, DOLK, 
DPP6, DSC2, DSG2, DSP, DTNA, EFEMP2, ELN, EMD, EYA4, FBN1, FBN2, FHL1, FHL2, FKRP, FKTN, FXN, GAA, 
GATAD1, GCKR, GJA5, GLA, GPD1L, GPIHBP1, HADHA, HCN4, HFE, HRAS, HSPB8, ILK, JAG1, JPH2, JUP, KCNA5, 
KCND3, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, KLF10, KRAS, LAMA2, LAMA4, LAMP2, 
LDB3, LDLR, LDLRAP1, LMF1, LMNA, LPL, LTBP2, MAP2K1, MAP2K2, MIB1, MURC, MYBPC3, MYH11, MYH6, 
MYH7, MYL2, MYL3, MYLK, MYLK2, MYO6, MYOZ2, MYPN, NEXN, NKX2-5, NODAL, NOTCH1, NPPA, NRAS, PCSK9, 
PDLIM3, PKP2, PLN, PRDM16, PRKAG2, PRKAR1A, PTPN11, RAF1, RANGRF, RBM20, RYR1, RYR2, SALL4, SCN1B, 
SCN2B, SCN3B, SCN4B, SCN5A, SCO2, SDHA, SEPN1, SGCB, SGCD, SGCG, SHOC2, SLC25A4, SLC2A10, SMAD3, 
SMAD4, SNTA1, SOS1,SREBF2, TAZ, TBX20, TBX3, TBX5, TCAP, TGFB2, TGFB3, TGFBR1, TGFBR2, TMEM43, TMPO, 
TNNC1, TNNI3, TNNT2, TPM1, TRDN, TRIM63, TRPM4, TTN, TTR, TXNRD2, VCL, ZBTB17, ZHX3, ZIC3
Figure 1. A) Pedigree of the studied family. The solid symbol indicates clinically affected subjects. The arrow denotes 
the proband. Symbols (+) and (-) indicate TAZ mutation carriers and non-carriers in X-chromosome, respectively. The 
absence of a symbol denotes that genetic analysis was not performed; B) NGS reads detecting mutation in intron-exon 
junction; C) Electrophoregram showing the DNA sequence for the junction of intron 2 and exon 3 in TAZ gene.
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effects on splicing were shown for the base changes iden-
tified in the same locus - c.239-1G>C and c.239-1G>A. 
The first one abolishes splicing of intron 2, the second 
one reconstitutes the splice site with a 1 base shift 3. In 
any case, the mutations interfere with the translation of 
tafazzin and result in BTHS. 
Mutations causing BTHS are of several types includ-
ing splice site mutations, frameshifts, insertions, deletions, 
nonsense, and missense mutations. They lead to decreased 
or missing tafazzin enzymatic activity, with correspond-
ingly more or less global changes in cardiolipin content 
and composition associated with the disease severity. Un-
fortunately, not for all TAZ gene mutations the correlation 
between genotype and phenotype is apparent 10.
Whited et al. (2013) developed and applied a 
BTHS-mutant panel in the yeast Saccharomyces cerevisi-
ae. The authors introduced disease-causing variants into 
the Taz1p yeast ortholog to investigate loss-of-function 
mechanisms of tafazzin. As a result, seven functional 
classes of BTHS mutations were defined: (1) non-func-
tional proteins resulted from frameshifts and splice-site 
variants, (2) submitochondrial mislocalization and er-
roneous aggregation of products, (3) altered assembly 
of tafazzin, (4) catalytically inactive proteins, (5) low 
expression of tafazzin, (6) products unable to engage in 
stable productive assemblies (7) temperature-sensitive 
proteins  11. The processes of cardiolipin biosynthesis 
and remodeling are conserved from yeast to humans and 
therefore identified mechanisms bring us closer to the un-
derstanding of the genetic basis and clinical variability of 
BTHS. Later some of these functional classes were docu-
mented in human tafazzin within human cells 12.
In conclusion, this is the first description of 
c.239-1_239delinsTT variant causing the Barth syn-
drome. This splice-site variant can be considered as 
pathogenic for the following reasons: abnormal splicing 
Figure 2. A) Electrophoretic analysis of the RT-PCR products. P – proband, M – mother. The asterisks indicate bands 
extracted from gel and sequenced. The smaller PCR-product (204 bp) in agarose gel electrophoresis corresponds to 
a transcript without exon 3; B) TAZ gene diagram showing mutation location and its effect on splicing; C) Sequence 
analysis of RT-PCR products from the proband (P) and mother (M) revealed skipping of exon 3 in proband.
Larysa Sivitskaya et al.
92
of the TAZ leading to the skipping of the exon 3 (PVS1), 
de novo variant in the family without a history of DCM or 
heart failure (PS2), typical clinical phenotype observed in 
TAZ mutation carriers (PP4), absence in population data-
bases Exome Sequencing Project, 1000 Genomes Project 
and Exome Aggregation Consortium (PM2).
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